samedan logo
 
 
 
spacer
home > ebr > summer 2004 > editor's letter
PUBLICATIONS
European Biopharmaceutical Review

Editor's Letter

As we bring you the summer issue of EBR, there appear to be guarded grounds for continued optimism towards an upswing in the European biotechnology industry. As evidenced by the upbeat mood of the US industry at the recent Annual BIO Convention, this new optimism seems to be based on tangible measures of an industry regaining its feet. For example, increasing numbers of biologic drugs (25 out of 37) approved by the FDA in 2003, coupled to decreasing product review timeframes by the FDA, led to renewed investor interest and the second most successful financing year in the US industry's history in 2003 ($19 billion in public and private funds). However, the situation in Europe isn't quite that rosy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Helen Abbott, Technology Consultant at London Technology Network
spacer
Dr Helen Abbott
spacer
spacer
spacer
Lucy George
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ICON named best Contract Research Organisation in latest string of awards and recognitions

ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organisations, is proud to announce it was named the “Best Contract Research Organisation” of 2021 during the 17th Annual Scrip Awards ceremony on 2 December.
More info >>

White Papers

Sterile Vials Made of Tubular Glass

Gerresheimer AG

Gx® RTF vials powered by Ompi EZ-fill® enhance flexibility by facilitating packaging needs from clinical stage to industrialization with the common goal to minimize customer product risks and optimize total cost of ownership. Gerresheimer combines the competencies in converting glass tubes to serum/ injection vials and ready-to-fill processing for our pharma and biotech customers.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement